Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retapamulin vs Sodium Fusidate in Impetigo
NCT00133874Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2005
- Primary completion
- Sep 2005
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, single-blind trial of retapamulin in impetigo (2 arms), sponsored by GSK. Primary endpoint: Clinical response assessed at end of therapy visit at 7 days. Started Apr 2005; status: completed.
02
Drugs
retapamulin
03
Conditions
impetigo
Beyond the preview
Go deeper on NCT00133874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00133874.